Phase 2 trial tests fruquintinib plus chemotherapy in RAS-mutant CRC

◆ TRIAL DATA

Phase 2 trial tests fruquintinib plus chemotherapy in RAS-mutant CRC — Journal of Clinical Oncology

A multicenter, open-label phase 2 study evaluated fruquintinib (a targeted therapy) combined with FOLFIRI or mFOLFOX6 chemotherapy as second-line treatment for patients with RAS-mutant metastatic colorectal cancer. RAS mutations are present in about 40-50% of colorectal cancers and often limit treatment options.